Field of Study
Neuroscience, Pharmacotherapeutics, Regenerative medicine
Keywords
Neurodegenerative diseases, Drug discovery & development, iPS cells, RT-Quic
Lab URL
https://www.gifu-pu.ac.jp/lab/yakuchi/
治療法のない神経難病疾患の病態を解明し、根本的な薬物治療薬の開発を目指す。
Development of innovative drugs for neurodegenerative diseases
  • 教授 位田 雅俊 Professor Inden Masatoshi Ph.D. inden
  • 講師 栗田 尚佳 Associate Professor Kurita Hisaka PhD. kurita
  • 助教 大内 一輝 Assistant Professor Ohuchi Kazuki Ph.D. ohuchi-ka

研究テーマ Research Subjects

 薬物治療学研究室では、神経変性疾患の疾患基礎研究を通じて「創薬」につながる画期的な発見を目指すと同時に、研究のできる・わかる「人財」を社会へ還元することを目標として研究を行っています。主たる対象疾患は、アルツハイマー病、パーキンソン病、筋萎縮性側索硬化症(ALS)、特発性大脳基底核石灰化症(IBGC) です。また、神経の再生・発達過程における環境要因の影響にも興味をもって研究をしています。私たちは目標を達成するために、分野の垣根を越えた国内外の共同研究や産学連携を促進することや、iPS 細胞、ゲノム解析・編集、分子イメージング、AIなどの最新の技術を積極的に取り入れて活用しています。

The purpose of our research is to develop new effective medicine for neurodegenerative diseases. They are amyotrophic lateral sclerosis disease (ALS), Alzheimer's disease (AD) and Parkinson's disease (PD). Our research is focused primarily on idiopathic basal ganglia calcification (IBGC) that is traditionally called as'Fahr's disease (FD)'. We have been investigating neurodegenerative diseases from genomic studies, functional studies using iPS cells and qualitative research data based on personal interviews. In addition, we have been working on neurodegenerative diseases from the viewpoints of the regeneration and development of the nervous system. To achieve our goals, we promote domestic and international joint research and industry-academia collaboration across disciplines, and actively incorporate and utilize the latest technologies such as iPS cells, genome analysis and editing, imaging, and AI.

yakubutsu-chiryougaku.png

研究課題 Research Objectives

  1. 認知症、パーキンソン病、筋萎縮性側索硬化症(ALS)などの神経変性疾患に共通した発症機序解明と再生・創薬研究
    The clarification of the pathophysiological mechanism and the development of new agents for neurodegenerative diseases such AD, PD and ALS based on the aspect of the neuronal death
  2. 特発性大脳基底核石灰化症(IBGC) の病態解明と治療薬開発
    The research of the pathophysiology, the accurate diagnostic methods and the therapeutic strategies on idiopathic basal ganglia calcification (IBGC) which is also traditionally called 'Fahr's disease (FD)'
  3. 胎生期から生涯における環境要因によるエピジェネティクス撹乱の神経機能に及ぼす影響の解明
    Elucidation of the effects of epigenetic disturbances caused by environmental factors on neural functions.

最近の研究成果 Research Results

  1. Go, S., Kurita, H., Hatano, M., Matsumoto, K., Nogawa, H., Fujimura, M., Inden, M., Hozumi, I., DNA methyltransferase- and histone deacetylase-mediated epigenetic alterations induced by low-level methylmercury exposure disrupt neuronal development, Arch Toxicol, 95, 1227-1239 (2021).
  2. Ito, T., Inden, M., Ueda, T., Asaka, Y., Kurita, H., Hozumi, I., The neuroprotective effects of activated a7 nicotinic acetylcholine receptor against mutant copper-zinc superoxide dismutase 1-mediated toxicity. Sci Rep, 10, 22157 (2020).
  3. Takase, N., Inden, M., Hirai, S., Yamada, Y., Kurita, H., Takeda, M., Yamaguchi, E., Itoh, A., Hozumi, I., The Novel gem-Dihydroperoxide 12AC3O Suppresses High Phosphate-Induced Calcification via Antioxidant Effects in p53LMAco1 Smooth Muscle Cells, Int J Mol Sci, 21, 4628 (2020).
  4. Kurita, H., Yabe, S., Ueda, T., Inden, M., Kakita, A., Hozumi, I.. MicroRNA-5572 Is a Novel MicroRNA-Regulating SLC30A3 in Sporadic Amyotrophic Lateral Sclerosis, Int J Mol Sci, 21, 4482 (2020).
  5. Sekine, S.I., Kaneko, M., Tanaka, M., Ninomiya, Y., Kurita ,H., Inden, M., Yamada, M., Hayashi, Y., Inuzuka, T., Mitsui, J., Ishiura, H., Iwata, A., Fujigasaki, H., Tamaki, H., Tamaki, R., Kito, S., Taguchi, Y., Tanaka, K., Atsuta, N., Sobue, G., Kondo, T., Inoue, H., Tsuji, S., Hozumi, I., Functional evaluation of PDGFB-variants in idiopathic basal ganglia calcification, using patient-derived iPS cells, Sci Rep, 9, 5698 (2019)